TY - JOUR AU - Kramer, Dany Geraldo AU - Silva, Maria Josilene Leonardo Da AU - Silva, Gislanne Stéphanne Estevam Da AU - Moura, Ana Maria Marinho Andrade De AU - Junior, Geraldo Barroso Cavalcanti AU - Sousa, Anesio Mendes De AU - Silva, Ana Elizabeth Alves Da PY - 2020/04/30 Y2 - 2024/03/28 TI - FAVIPIRAVIR AS A POTENTIAL DRUG IN THE TREATMENT OF COVID-19 JF - International Journal of Research -GRANTHAALAYAH JA - Int. J. Res. Granthaalayah VL - 8 IS - 4 SE - Articles DO - 10.29121/granthaalayah.v8.i4.2020.2 UR - https://www.granthaalayahpublication.org/journals/granthaalayah/article/view/IJRG20_B04_3242 SP - 7-12 AB - <p align="justify">Favipiravir is a drug developed for use against influenza and has been used successfully in other infectious conditions. After being internalized in the cell, the substance is phosphoribosylated acting on the RNA polymerase, and thus inhibiting replication and RNA viruses. Thus, the present study aimed to discuss the potential use of favipiravir in coronovavirus infections. There have been few studies involving favipiravir in COVID 19, however there is a report of recovery in more than 70% of patients diagnosed with pneumonia. However, new studies need to be carried out, mainly randomized clinical trials, so that the potential use of favipiravir in coronoviruses is adequately grounded.</p> ER -